JP2021514365A - 肝疾患を処置するための方法及び組成物 - Google Patents

肝疾患を処置するための方法及び組成物 Download PDF

Info

Publication number
JP2021514365A
JP2021514365A JP2020543919A JP2020543919A JP2021514365A JP 2021514365 A JP2021514365 A JP 2021514365A JP 2020543919 A JP2020543919 A JP 2020543919A JP 2020543919 A JP2020543919 A JP 2020543919A JP 2021514365 A JP2021514365 A JP 2021514365A
Authority
JP
Japan
Prior art keywords
mice
ire1α
liver
stf
fat diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020543919A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019158689A5 (https=
JP2021514365A5 (https=
Inventor
バイリー−メートル・ル，ベアトリス
グアル，フィリップ
トラン，アルベール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Nice Sophia Antipolis UNSA
Centre Hospitalier Universitaire de Nice
Original Assignee
Universite de Nice Sophia Antipolis UNSA
Centre Hospitalier Universitaire de Nice
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Nice Sophia Antipolis UNSA, Centre Hospitalier Universitaire de Nice filed Critical Universite de Nice Sophia Antipolis UNSA
Publication of JP2021514365A publication Critical patent/JP2021514365A/ja
Publication of JPWO2019158689A5 publication Critical patent/JPWO2019158689A5/ja
Publication of JP2021514365A5 publication Critical patent/JP2021514365A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2020543919A 2018-02-16 2019-02-15 肝疾患を処置するための方法及び組成物 Pending JP2021514365A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305169.7 2018-02-16
EP18305169 2018-02-16
PCT/EP2019/053807 WO2019158689A1 (en) 2018-02-16 2019-02-15 Methods and compositions for treating liver diseases

Publications (3)

Publication Number Publication Date
JP2021514365A true JP2021514365A (ja) 2021-06-10
JPWO2019158689A5 JPWO2019158689A5 (https=) 2022-02-18
JP2021514365A5 JP2021514365A5 (https=) 2022-02-18

Family

ID=61283136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543919A Pending JP2021514365A (ja) 2018-02-16 2019-02-15 肝疾患を処置するための方法及び組成物

Country Status (4)

Country Link
US (2) US20210085643A1 (https=)
EP (1) EP3752135A1 (https=)
JP (1) JP2021514365A (https=)
WO (1) WO2019158689A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230053055A (ko) * 2021-10-13 2023-04-21 단국대학교 천안캠퍼스 산학협력단 쌍별귀뚜라미 가수분해물을 유효성분으로 함유하는 비알코올성 지방간 질환 예방 또는 개선용 식품 조성물 및 이의 제조방법

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4355356A4 (en) * 2021-06-15 2025-05-14 Yale University Compounds and methods for treating or preventing autosomal dominant polycystic kidney disease (ADPKD), autosomal dominant polycystic liver disease (ADPLD), and/or autosomal recessive polycystic kidney disease
CN113647359A (zh) * 2021-08-15 2021-11-16 芜湖职业技术学院 注射衣霉素诱导急性肝损伤小鼠模型的构建方法
CN114712514B (zh) * 2022-03-03 2023-03-31 浙江大学 用于局部和全身性减脂的纳米制剂及其应用
CN116549442A (zh) * 2023-06-08 2023-08-08 复旦大学 Stf-083010在制备防治主动脉夹层药物中的应用
CN119185312B (zh) * 2024-10-11 2026-04-21 浙江大学 盐酸胺苯吖啶在制备防治纤维化疾病的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525281A (ja) * 2010-04-05 2013-06-20 マンカインド コーポレ−ション ＩＲＥ−１αインヒビター
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020019107A1 (en) * 2018-07-23 2020-01-30 Fosun Orinove Pharmatech, Inc. IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525281A (ja) * 2010-04-05 2013-06-20 マンカインド コーポレ−ション ＩＲＥ−１αインヒビター
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLOOD CANCER JOURNAL, vol. 2, JPN6023011830, 2012, pages 79 - 11, ISSN: 0005124180 *
GASRTOENTEROLOGY, vol. Vol. 150, No. 4, Suppl. 1, JPN6023011829, 2016, pages 1089 - 1662, ISSN: 0005124179 *
PLOS ONE, vol. 12, no. 3, JPN6023011828, 2017, pages 0170591 - 18, ISSN: 0005124178 *
ZHAO N ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 128, no. 4, JPN6023011298, April 2018 (2018-04-01), pages 1283 - 1299, ISSN: 0005124181 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230053055A (ko) * 2021-10-13 2023-04-21 단국대학교 천안캠퍼스 산학협력단 쌍별귀뚜라미 가수분해물을 유효성분으로 함유하는 비알코올성 지방간 질환 예방 또는 개선용 식품 조성물 및 이의 제조방법
KR102718502B1 (ko) * 2021-10-13 2024-10-16 단국대학교 천안캠퍼스 산학협력단 쌍별귀뚜라미 가수분해물을 유효성분으로 함유하는 비알코올성 지방간 질환 예방 또는 개선용 식품 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
EP3752135A1 (en) 2020-12-23
US20210085643A1 (en) 2021-03-25
WO2019158689A1 (en) 2019-08-22
US20240024281A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
JP2021514365A (ja) 肝疾患を処置するための方法及び組成物
EP3206703B1 (en) Peptide for treating pancreatic cancer
Shi et al. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer
Maayah et al. Resveratrol reduces cardiac NLRP3‐inflammasome activation and systemic inflammation to lessen doxorubicin‐induced cardiotoxicity in juvenile mice
US9155723B2 (en) Anti-CXCR4 as a sensitizer to cancer therapeutics
KR102755267B1 (ko) iNOS-억제 조성물들 및 이들의 유방암 치료제로서의 용도
Geng et al. 10-hydroxy-2-decenoic acid prevents osteoarthritis by targeting aspartyl β hydroxylase and inhibiting chondrocyte senescence in male mice preclinically
Wang et al. Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer
Anastasio et al. SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells
Patel et al. Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1
Chen et al. Tirzepatide protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via PI3K/Akt signaling
Lu et al. HBx induced upregulation of FATP2 promotes the development of hepatic lipid accumulation
CN112852961A (zh) 肺腺癌铁死亡敏感性标志物adcy10及其应用
Lee et al. Tpl2 inhibitors thwart endothelial cell function in angiogenesis and peritoneal dissemination
Zhang et al. Mefunidone ameliorates acute liver failure in mice by inhibiting MKK4-JNK pathway
Zhang et al. SGK1 is involved in doxorubicin-induced chronic cardiotoxicity and dysfunction through activation of the NFκB pathway
KR20240035368A (ko) 고형암 환자의 화학요법 내성 억제용 약학 조성물 및 이의 용도
Wang et al. IFNγ blockade in capillary leak site improves tumour chemotherapy by inhibiting lactate-induced endocytosis of vascular endothelial-cadherins
US20180064789A1 (en) Methods and pharmaceutical compositions for the treatment of pancreatic cancer
US20230365673A1 (en) Means for reducing radio- and chemotherapy resistance and adverse effects
Li et al. Squid-derived protamine: A natural basic protein and its PEGylated derivative as anti-cancer agents in hepatocellular carcinoma
Tang et al. USP13 ameliorates metabolic dysfunction-associated steatohepatitis through targeting PTEN
Lei Activation of α7nAChR preserves intestinal barrier integrity and ameliorates cholestasis liver fibrosis in mice by enhancing the HO-1/STAT3 signaling to inhibit NF-κB activation
Wang et al. Gallic acid enhances the antitumor activity of Icotinib hydrochloride in non-small cell lung cancer via of Hippo-YAP signaling pathway in vitro and in vivo
Schniers Unveiling the tumor promoting role of nutrient transporters, SLC15A1 and SLC6A14 in pancreatic ductal adenocarcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240206